Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.

Mafalda C RamosVolker FoosAnastasia UstyugovaNikco HauPranav GandhiMark Lamotte

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2019)

Boehringer Ingelheim International GmbH.